IMRT is medically necessary when ANY one of the following indications is present:
Top-level clinical indications: A. Age < 18 years with a solid tumor.
Policy I.A; pediatric solid tumors
Top-level clinical indications: B. Medically inoperable patient with diagnosis of cancer where dose escalation is required.
Policy I.B
Top-level clinical indications: C. Primary malignant or benign bone tumors.
Policy I.C
Top-level clinical indications: D. Re-irradiation where cumulative critical structure dose would exceed tolerance dose.
Policy I.D
Top-level clinical indications: E. Indications by cancer site (any one of the site-specific sub-indications below).
Policy I.E
Central Nervous System indications: Ocular tumors including intraocular melanomas; tumors that approach or are located at the base of skull; primary CNS tumors, primary spine, or metastatic tumors to the spine or spinal cord where organ-at-risk tolerance may be exceeded with 3-D conformal treatments; primary and metastatic tumors requiring craniospinal irradiation; brain metastases requiring hippocampal-sparing whole brain radiotherapy.
Policy I.E.1
Head and Neck indications: Definitive, adjuvant, or palliative treatment of primary/secondary head and neck cancers or draining lymphatics of the neck (including but not limited to nasopharynx, nasal cavity, paranasal sinuses, oropharynx, oral cavity, hypopharynx, larynx, thyroid, salivary glands); cutaneous tumors with cranial nerve invasion to the base of skull, cavernous sinus, and/or brainstem; mucosal melanoma; occult primary malignancies of the head and neck.
Policy I.E.2
Breast indications: Bilateral breast cancers requiring nodal treatment on at least one side; definitive treatment with unfavorable anatomy that would deliver unacceptably high doses to organs-at-risk; early-stage disease with unacceptably high cardiac dose using conventional techniques; accelerated partial breast irradiation (APBI) regardless of laterality; targeting internal mammary lymph nodes; limited ipsilateral arm range of motion requiring arms-down positioning; post-mastectomy radiotherapy with bilateral implant-based reconstruction; whole breast radiotherapy in patients with bilateral augmentation implants.
Policy I.E.3
Thoracic indications: Primary or secondary mediastinal tumors (including thymic tumors, mediastinal tumors, mediastinal lymphomas and thoracic sarcomas); early-stage lung cancer for which SBRT is not feasible due to anatomic considerations; locally advanced lung cancer where IMRT significantly reduces dose to normal tissues (e.g., bilateral mediastinal disease, paraspinal tumors, N3 disease, reducing esophageal dose); malignant pleural mesothelioma.
Policy I.E.4
Gastrointestinal indications: Hepatocellular cancer, bile duct, gallbladder and cholangiocarcinoma; primary cancers of the esophagus and gastroesophageal junction; abdominal malignancies including pancreatic, gastric and adrenal cancers; primary and secondary liver cancers; anal and colorectal cancers.
Policy I.E.5
Sarcoma indications: Retroperitoneal sarcomas; desmoid tumors; endometrial cancer; soft tissue sarcoma when organ-at-risk dose constraints cannot be met.
Policy I.E.6
Pelvic/Gynecological indications: Cervical cancer; vulvar and vaginal cancers; endometrial cancer.
Policy I.E.7
Genitourinary indications: Prostate cancer; renal cancer; bladder cancer; penile cancer; ureteral cancer.
Policy I.E.8